본문 바로가기
  • Home

Quality Control of Majoon-e-Nisyan and its Acute Oral Toxicity Study in Experimental Rats

  • CELLMED
  • Abbr : CellMed
  • 2021, 11(1), pp.2-2
  • DOI : 10.5667/CellMed.2021.0002
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : September 19, 2020
  • Accepted : January 6, 2021
  • Published : February 26, 2021

Masud Shaikh 1 Gulam M. Husain 1 Mohammed Abdul Rasheed Naikodi 1 Munawwar H. Kazmi 1 Uzma Viquar 1

1National Research Institute of Unani Medicine for Skin Disorders (formerly CRIUM)

Accredited

ABSTRACT

The clinical condition Amnesia causes difficulty in learning new information and the inability to recall past events. It is primarily concerned with recent memory loss. Majoon-e-Nisyan (MJN) is a polyherbal Unani formulation, present in a semi-solid form. It is widely used potent drug of the Unani System of Medicine (USM) for treating Nisyan (amnesia). In the present study polyherbal Unani formulation, MJN has been studied for its quality control and acute toxicity. Standardization (quality control) of drugs deals with drug identity, drug quality and purity determination. Standardization of MJN had been done as per the Unani pharmacopoeial parameters approved by World Health Organization (WHO) - Pharmacognostical parameters, Physico-chemical parameters, high-performance thin-layer chromatography (HPTLC), microbial load, aflatoxin, and heavy metals. Solvents and chemicals used in the study were of analytical grade and used instrument were calibrated. By conducting an acute oral toxicity study in rats, the safety of MJN was assessed. The limit test method of OECD guideline 425 was followed in the study. Results of standardization and standard operating procedures (SOPs) for preparation of MJN may serve as the standard reference in the future. The data generated in the study for the quality control of MJN proved the quality of formulation and shows that MJN is not toxic in rats following acute dosing up to 2000 mg/kg bw. The data obtained in the paper for MJN may be used as a standard guideline for preparation of the formulation which can save time, cost, and resources for future research endeavours.

Citation status

* References for papers published after 2023 are currently being built.